Our laboratory has already developed the ASO-mediated exon skipping therapy for the male XLAS model mice (with specific Col4a5 nonsense variant) and reported its effects in 2020 (50). This evidence concerns the gene COL4A5 and X-linked hydrocephalus with stenosis of the aqueduct of Sylvius.